TNFSF10 and neoplasm: The therapeutic strategy in clinical studies is to use recombinant soluble TRAIL (sTRAIL) or TRAIL receptor agonists (TRAs) against TRAIL-receptors alone or in combination with chemical drugs for tumor therapy, respectively [3–6].